# Faeth Therapeutics, Inc.: overview FTH · Nasdaq · CIK 1829802 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/fth.md) · [Financials](/companies/fth/financials.md) · [Filings](/companies/fth/filings.md) · [Insiders](/companies/fth/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(5.77)](/filings/0001193125-25-281590.md) | not reported | [(5.45)](/filings/0001193125-26-225333.md) | [(3.91)](/filings/0001193125-26-331562.md) | [(3.62)](/filings/0001193125-25-281590.md) | not reported | [(131.45)](/filings/0001193125-26-225333.md) | [(2.84)](/filings/0001193125-26-331562.md) | | Free cash flow | $m | [(5.5) d](/filings/0001193125-25-281590.md) | [(5.8) d](/filings/0001193125-26-132014.md) | [(7.1)](/filings/0001193125-26-225333.md) | [(5.9) d](/filings/0001193125-26-331562.md) | [(3.6) d](/filings/0001193125-25-281590.md) | [(3.9) d](/filings/0001193125-26-132014.md) | [(10.7)](/filings/0001193125-26-225333.md) | [(15.7) d](/filings/0001193125-26-331562.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.33)](/filings/0000950170-23-010432.md) | [(1.58)](/filings/0000950170-24-023148.md) | [(1.22)](/filings/0000950170-25-046338.md) | [(24.01)](/filings/0001193125-26-132014.md) | [(16.72)](/filings/0001193125-26-132014.md) | | Free cash flow | $m | [(32.3)](/filings/0000950170-23-010432.md) | [(39.3)](/filings/0000950170-24-023148.md) | [(32.2)](/filings/0000950170-25-046338.md) | [(24.8)](/filings/0001193125-26-132014.md) | [(20.5)](/filings/0001193125-26-132014.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/fth/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $50.5m | 2,020,103 | | Added +1,985,554 | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $36.1m | 1,444,039 | | New +1,444,039 | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $32.2m | 1,286,411 | | New +1,286,411 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $26.1m | 1,042,198 | | Added +1,025,993 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $18.1m | 722,020 | | New +722,020 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $18.1m | 722,020 | | Unchanged | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $18.1m | 722,020 | | Added +692,020 | | [Fairmount Funds Management LLC](/funds/1802528.md) | 2026-06-30 | $18.1m | 722,020 | | New +722,020 | | [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $15.7m | 629,467 | | Added +503,465 | | [B Group, Inc.](/funds/2043476.md) | 2026-06-30 | $15.3m | 610,169 | | New +610,169 | ## Recent filings [All 448 filings](/companies/fth/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 07:33 ET | [8-K](/filings/0001193125-26-432688.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-432688 | | 2026-09-17 | 16:15 ET | [8-K](/filings/0001193125-26-394360.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-394360 | | 2026-08-04 | 07:40 ET | [10-Q](/filings/0001193125-26-331562.md) | Quarterly report, period 2026-06-30 | 0001193125-26-331562 | | 2026-08-04 | 07:40 ET | [8-K](/filings/0001193125-26-331563.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331563 | | 2026-07-23 | 17:15 ET | [8-K](/filings/0001193125-26-314591.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-314591 | | 2026-06-18 | 17:13 ET | [8-K](/filings/0001193125-26-276093.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-276093 | | 2026-06-15 | 08:16 ET | [8-K](/filings/0001193125-26-270330.md) | 1.02 Termination of a material agreement; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270330 | | 2026-06-10 | 16:21 ET | [8-K](/filings/0001193125-26-265879.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-265879 | | 2026-06-02 | 09:01 ET | [10-K/A](/filings/0001193125-26-252637.md) | Annual report, amended, period 2025-12-31 | 0001193125-26-252637 | | 2026-05-22 | 16:01 ET | [8-K](/filings/0001193125-26-236820.md) | 8.01 Other events | 0001193125-26-236820 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-132014.md), filed Mar 30, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1829802 - Tickers: FTH - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:18 ET. No prices; not investment advice.